ESLA:NASDAQ, Estrella Immunopharma, Inc.
Why ESLA stock fell on November 12
Estrella Immunopharma, Inc. fell 34.6%
on Thursday, November 12, 2026, on 1,585,900 shares.
No headline about ESLA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
ESLA stock overview
Estrella Immunopharma, Inc. (ESLA:NASDAQ) closed at $0.332 on November 17, 2026,
down 12.74% on the day.
The stock trades 85.4% below its 52-week high of $2.27
and 38.2% above its 52-week low of $0.240.
Over the past year, it lost 79.1%.
Estrella Immunopharma, Inc. is part of the Funds & Shells sector.
Key figures
- Price
- $0.332
- Day change
- -12.74%
- Volume
- 747,442
- Average volume
- 2,013,696
- Market cap
- 14M+
- 52-week range
- $0.240 – $2.27
- 50-day average
- $0.539
- 200-day average
- $0.961
Price action over the past year
In 252 trading sessions since November 17, 2025, ESLA closed higher on 96 days (38%).
Its best day was October 15, 2026 (+68.24%) and its worst was November 12, 2026 (-34.63%).
The stock moved 10% or more in a single session 39 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
ESLA news
-
Nov 16, 2026:
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
-
Nov 16, 2026:
Estrella Immunopharma Highlights ARTEMIS T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
-
Oct 26, 2026:
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
-
Oct 15, 2026:
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
-
Oct 14, 2026:
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkins Lymphoma
-
Oct 14, 2026:
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
-
Oct 9, 2026:
BC-Most Active Stocks
-
Aug 26, 2026:
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
About Estrella Immunopharma, Inc.
TradeUP Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Similar stocks
Find more stocks like ESLA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.